BR112021008524A8 - 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8 - Google Patents

2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8

Info

Publication number
BR112021008524A8
BR112021008524A8 BR112021008524A BR112021008524A BR112021008524A8 BR 112021008524 A8 BR112021008524 A8 BR 112021008524A8 BR 112021008524 A BR112021008524 A BR 112021008524A BR 112021008524 A BR112021008524 A BR 112021008524A BR 112021008524 A8 BR112021008524 A8 BR 112021008524A8
Authority
BR
Brazil
Prior art keywords
disorders
inhibitors
nicotinamides
nav
heteroaryl
Prior art date
Application number
BR112021008524A
Other languages
English (en)
Other versions
BR112021008524A2 (pt
Inventor
Arasappan Ashok
M Bell Ian
J Breslin Michael
James Bungard Christopher
S Burgey Christopher
R Chobanian Harry
M Cox Jason
Guy Guiadeen Deodial
L G Jones Kristen
E Layton Mark
Liu Hong
Liu Jian
J Perkins James
J Stachel Shawn
M Suen-Lai Linda
T Ginnetti Anthony
Wu Zhe
Original Assignee
Merck Sharp & Dohme
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme
Priority to BR122023020853-6A priority Critical patent/BR122023020853A2/pt
Publication of BR112021008524A2 publication Critical patent/BR112021008524A2/pt
Publication of BR112021008524A8 publication Critical patent/BR112021008524A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Compostos novos da fórmula estrutural (I), e os sais farmaceuticamente aceitáveis dos mesmos, são inibidores de atividade de canal Nav1.8 e podem ser úteis no tratamento, prevenção, gerenciamento, melhora, controle e supressão de doenças mediadas por atividade de canal Nav1.8. Os compostos da presente invenção podem ser úteis no tratamento, prevenção ou gerenciamento de distúrbios de dor, distúrbios de tosse, distúrbios de coceira aguda e distúrbios de coceira crônica.
BR112021008524A 2018-11-02 2019-10-31 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8 BR112021008524A8 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122023020853-6A BR122023020853A2 (pt) 2018-11-02 2019-10-31 Compostos 2-amino-n-heteroaril-nicotinamidas, composição farmacêutica que os compreende e usos dos mesmos

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754742P 2018-11-02 2018-11-02
US62/754,742 2018-11-02
PCT/US2019/058999 WO2020092667A1 (en) 2018-11-02 2019-10-31 2-amino-n-heteroaryl-nicotinamides as nav1.8 inhibitors

Publications (2)

Publication Number Publication Date
BR112021008524A2 BR112021008524A2 (pt) 2021-08-03
BR112021008524A8 true BR112021008524A8 (pt) 2023-02-07

Family

ID=68655658

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122023020853-6A BR122023020853A2 (pt) 2018-11-02 2019-10-31 Compostos 2-amino-n-heteroaril-nicotinamidas, composição farmacêutica que os compreende e usos dos mesmos
BR112021008524A BR112021008524A8 (pt) 2018-11-02 2019-10-31 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122023020853-6A BR122023020853A2 (pt) 2018-11-02 2019-10-31 Compostos 2-amino-n-heteroaril-nicotinamidas, composição farmacêutica que os compreende e usos dos mesmos

Country Status (27)

Country Link
US (3) US20210387966A1 (pt)
EP (1) EP3873893A1 (pt)
JP (1) JP7288051B2 (pt)
KR (1) KR20210086687A (pt)
CN (1) CN113272293B (pt)
AR (1) AR116939A1 (pt)
AU (2) AU2019372057A1 (pt)
BR (2) BR122023020853A2 (pt)
CA (1) CA3117927A1 (pt)
CL (1) CL2021001078A1 (pt)
CO (1) CO2021005553A2 (pt)
CR (1) CR20210209A (pt)
DO (1) DOP2021000082A (pt)
EA (1) EA202191177A1 (pt)
EC (1) ECSP21030066A (pt)
GE (1) GEP20237568B (pt)
IL (1) IL282468A (pt)
JO (1) JOP20210097A1 (pt)
MA (1) MA54076A (pt)
MX (1) MX2021005154A (pt)
MY (1) MY197128A (pt)
NI (1) NI202100029A (pt)
PE (1) PE20211693A1 (pt)
SG (1) SG11202104326TA (pt)
TW (1) TWI784207B (pt)
WO (1) WO2020092667A1 (pt)
ZA (1) ZA202102628B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3898616B1 (en) * 2018-12-20 2024-10-02 Amgen Inc. Heteroaryl amides useful as kif18a inhibitors
WO2021113627A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
WO2021257490A1 (en) 2020-06-17 2021-12-23 Merck Sharp & Dohme Corp. 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
JP7539545B2 (ja) * 2020-07-03 2024-08-23 武漢朗来科技発展有限公司 複素環化合物及びその使用
CN114591293A (zh) * 2020-12-07 2022-06-07 成都康弘药业集团股份有限公司 作为Nav1.8抑制剂的并环化合物及其用途
CN112457294B (zh) * 2021-01-27 2021-06-04 上海济煜医药科技有限公司 一种作为NaV1.8阻滞剂的化合物及其制备方法和用途
CA3217605A1 (en) * 2021-05-07 2022-11-10 Ashok Arasappan Aryl 3-oxopiperazine carboxamides and heteroaryl 3-oxopiperazine carboxamides as nav1.8 inhibitors
WO2022235859A1 (en) * 2021-05-07 2022-11-10 Merck Sharp & Dohme Llc Cycloalkyl 3-oxopiperazine carboxamides and cycloheteroalkyl 3-oxopiperazine carboxamides as nav1.8 inhibitors
BR112023025264A2 (pt) 2021-06-04 2024-02-20 Vertex Pharma Formas farmacêuticas sólidas e regimes posológicos compreendendo (2r,3s,4s,5r)-4-[[3- (3,4-difluoro-2-metóxi-fenil)-4,5-dimetil-5-(trifluorometil) tetra-hidrofuran-2-carbonil]amino ]piridina-2-carboxamida
CA3221960A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels
JP2024522292A (ja) 2021-06-04 2024-06-13 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのｎ－（ヒドロキシアルキル（ヘテロ）アリール）テトラヒドロフランカルボキサミド
CA3221788A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels
CN117794921A (zh) * 2021-06-04 2024-03-29 沃泰克斯药物股份有限公司 用于合成取代的四氢呋喃钠通道调节剂的方法
WO2022256676A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofuran analogs as modulators of sodium channels
WO2022256679A1 (en) 2021-06-04 2022-12-08 Vertex Pharmaceuticals Incorporated N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels
US11999699B2 (en) 2021-06-15 2024-06-04 Grünenthal GmbH Substituted pyrazole amides
WO2022268230A1 (zh) * 2021-06-25 2022-12-29 杭州英创医药科技有限公司 作为kif18a抑制剂的化合物
AR126669A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
AR126670A1 (es) 2021-08-02 2023-11-01 Eurofarma Laboratorios S A COMPUESTOS N-ACILIDRAZÓNICOS INHIBIDORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, COMPOSICIONES, USOS, MÉTODOS DE TRATAMIENTO DE ESTOS Y KITS
IL310928A (en) 2021-09-24 2024-04-01 Xenon Pharmaceuticals Inc Pyridine derivatives and their use as sodium channel activators
WO2023150201A2 (en) * 2022-02-04 2023-08-10 Latigo Biotherapeutics, Inc. Sodium channel blocking compounds, derivatives thereof, and methods of their use
AU2023255558A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
AU2023255771A1 (en) 2022-04-22 2024-10-31 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
WO2023205468A1 (en) 2022-04-22 2023-10-26 Vertex Pharmaceuticals Incorporated Heteroaryl compounds for the treatment of pain
TW202404969A (zh) 2022-04-22 2024-02-01 美商維泰克斯製藥公司 用於治療疼痛之雜芳基化合物
CN116947713A (zh) * 2022-04-25 2023-10-27 中国科学院上海药物研究所 并环类化合物及其应用
WO2023211990A1 (en) 2022-04-25 2023-11-02 Siteone Therapeutics, Inc. Bicyclic heterocyclic amide inhibitors of na v1.8 for the treatment of pain
WO2024041613A1 (zh) * 2022-08-24 2024-02-29 江苏恒瑞医药股份有限公司 杂环类化合物、其制备方法及其在医药上的应用
WO2024046253A1 (zh) * 2022-08-28 2024-03-07 上海汇伦医药股份有限公司 一种钠通道调节剂及其应用
WO2024123815A1 (en) 2022-12-06 2024-06-13 Vertex Pharmaceuticals Incorporated Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels
WO2024126648A1 (en) 2022-12-14 2024-06-20 Grünenthal GmbH SULFOXIMINES AS INHIBITORS OF NaV1.8
EP4385980A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Indazoles as inhibitors of nav1.8
EP4385979A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Multicyclic inhibitors of nav1.8
EP4385984A1 (en) 2022-12-14 2024-06-19 Grünenthal GmbH Pyridine-n-oxides as inhibitors of nav1.8
WO2024137984A1 (en) * 2022-12-22 2024-06-27 Accent Therapeutics, Inc. Inhibitors of kif18a and uses thereof
CN118324743A (zh) * 2023-04-19 2024-07-12 中国科学院上海药物研究所 Nav1.8抑制剂及其制备方法和用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6431779A (en) * 1987-07-28 1989-02-02 Hokuriku Pharmaceutical Pyrazine derivative
EP1809290A2 (en) * 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
KR20080109918A (ko) 2006-04-11 2008-12-17 버텍스 파마슈티칼스 인코포레이티드 전압 개폐 나트륨 채널의 억제제로서 유용한 조성물
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
JP5562859B2 (ja) 2007-10-11 2014-07-30 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なアリールアミド
JP5555169B2 (ja) 2007-10-11 2014-07-23 バーテックス ファーマシューティカルズ インコーポレイテッド 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド
US20110183958A1 (en) * 2008-10-17 2011-07-28 Merck Frosst Canada Ltd. Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
EP2246335A1 (de) 2009-02-17 2010-11-03 Bayer CropScience AG Aminopyrimidinamide als Schädlingsbekämpfungsmittel
JP2012254939A (ja) * 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
JP2013519732A (ja) 2010-02-17 2013-05-30 アムジエン・インコーポレーテツド 疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
JP2013543480A (ja) * 2010-10-18 2013-12-05 ラクオリア創薬株式会社 Ｔｔｘ−ｓ遮断薬としてのアリールアミド誘導体
RU2477723C2 (ru) 2011-06-16 2013-03-20 Общество С Ограниченной Ответственностью "Фьюжн Фарма" Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
ES2602140T3 (es) * 2011-06-27 2017-02-17 Newron Pharmaceuticals S.P.A. Derivados de arilalquilaminocarboxamida fluorados
BR112015018284B1 (pt) 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas como moduladores de canais de sódio, seus usos, e composição farmacêutica
PT3239134T (pt) * 2013-01-31 2021-01-28 Vertex Pharma Piridona amidas como moduladores dos canais de sódio
BR112015017997B1 (pt) 2013-01-31 2023-03-07 Vertex Pharmaceuticals Incorporated Amidas de quinolina e quinoxalina como moduladores de canais de sódio, seus usos, e composição farmacêutica
JP6337109B2 (ja) 2013-07-19 2018-06-06 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ ナトリウムチャネルの調節剤としてのスルホンアミド
EP3080134B1 (en) 2013-12-13 2018-08-01 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
RU2743074C2 (ru) * 2014-08-01 2021-02-15 Нуэволюшон А/С Соединения, активные по отношению к бромодоменам
JP2017214290A (ja) 2014-09-12 2017-12-07 田辺三菱製薬株式会社 芳香族カルボン酸アミド化合物
CN109153659A (zh) 2016-05-31 2019-01-04 翰林大学产学研合作团队 五元杂环衍生物、其制备方法及包含其的药剂学组合物
GB201615622D0 (en) * 2016-09-14 2016-10-26 Syngenta Participations Ag Improvements in or relating to organic compounds
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels

Also Published As

Publication number Publication date
AR116939A1 (es) 2021-06-30
DOP2021000082A (es) 2021-07-22
TW202031643A (zh) 2020-09-01
ECSP21030066A (es) 2021-05-31
IL282468A (en) 2021-05-31
AU2019372057A1 (en) 2021-05-27
JP7288051B2 (ja) 2023-06-06
CN113272293B (zh) 2024-06-14
BR112021008524A2 (pt) 2021-08-03
KR20210086687A (ko) 2021-07-08
US11377438B2 (en) 2022-07-05
US20200140411A1 (en) 2020-05-07
WO2020092667A1 (en) 2020-05-07
JOP20210097A1 (ar) 2023-01-30
AU2022287562B2 (en) 2024-08-01
MY197128A (en) 2023-05-26
CA3117927A1 (en) 2020-05-07
CR20210209A (es) 2021-05-20
TWI784207B (zh) 2022-11-21
JP2022506146A (ja) 2022-01-17
PE20211693A1 (es) 2021-09-01
AU2022287562A1 (en) 2023-02-02
ZA202102628B (en) 2023-10-25
US20210387966A1 (en) 2021-12-16
CL2021001078A1 (es) 2021-10-29
MA54076A (fr) 2022-02-09
WO2020092667A8 (en) 2021-05-20
BR122023020853A2 (pt) 2024-01-16
SG11202104326TA (en) 2021-05-28
CO2021005553A2 (es) 2021-07-30
EA202191177A1 (ru) 2021-07-28
NI202100029A (es) 2021-08-13
GEP20237568B (en) 2023-11-27
US20220289710A1 (en) 2022-09-15
CN113272293A (zh) 2021-08-17
EP3873893A1 (en) 2021-09-08
MX2021005154A (es) 2021-07-15

Similar Documents

Publication Publication Date Title
BR112021008524A8 (pt) 2-amino-n-heteroaril-nicotinamidas como inibidores de nav 1.8
BR112022024476A2 (pt) 5-oxopirrolidino-3-carboxamidas como inibidores de nav1.8
BR112022024450A2 (pt) 2-oxo-oxazolidina-5-carboxamidas como inibidores de nav1.8
BR112022025805A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir um distúrbio, condição ou doença
BR112023023186A2 (pt) 3-oxopiperazina carboxamidas de arila e 3-oxopiperazina carboxamidas de heteroarla como inibidores de nav1.8
BR112022017393A2 (pt) Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
BR112019024016A2 (pt) amidas de piridona deuteradas e profármacos das mesmas como moduladores de canais de sódio
BR112018076534A2 (pt) compostos heterocíclicos como imunomoduladores
EA201792214A1 (ru) Соединения замещенного хиназолина
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112018068565A2 (pt) combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos
MX2023013146A (es) Cicloalquil 3-oxopiperazin carboxamidas y cicloheteroalquil 3-oxopiperazin carboxamidas como inhibidores de nav1.8.
JO3789B1 (ar) التراكيب والوسائل العلاجية المعتمدة لمعالجة الامراض المتعلقة بالمتممة
BR112015017519A2 (pt) compostos e métodos para o tratamento de infecções bacterianas
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
NZ771735A (en) Compound for treatment or prevention of liver diseases
MX2019002607A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
CL2021000743A1 (es) Métodos para tratar trastornos mieloproliferativos
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
BR112022001660A2 (pt) Inibidores de calpaína e usos dos mesmos para o tratamento de distúrbios neurológicos
WO2020101790A3 (en) Methods of using a phenoxypropylamine compound to treat pain
WO2019066548A3 (ko) 심부전의 예방 또는 치료용 약학적 조성물
EA202192544A1 (ru) Новые ингибиторы калиевых каналов

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERCK SHARP AND DOHME LLC (US)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122023020853-6 PROTOCOLO 870230089149 EM 06/10/2023 18:16.